Review Papers Claim by Claim

 Quick Explanation Copied

 Long Explanation

Evidence that Ubp3 is intrinsically active without Bre5

The core result rests on three complementary substrates. In the Ub-AMC fluorescence assay, Ubp3 and the commercial Usp2 control released AMC, while Bre5 alone and catalytic-dead Ubp3_C469A showed no signal; importantly, the isolated catalytic domain (Ubp3_Cat, residues 407–912) also cleaved Ub-AMC efficiently Ub-AMC activity evidence. Adding Bre5 at 0.5- to 10-fold molar excess left initial velocities unchanged (Figure 5B), and Ubp3 cleaved a Ub-GFP fusion over 20 min by SDS-PAGE without Bre5 Bre5-dose independence and Ub-GFP cleavage. This directly contradicts Cohen et al.'s proposal that Bre5 is required for Ubp3 activity Original Bre5 cofactor model.

NanoDSF gives mechanistic support: full-length Ubp3 (47.82 ± 0.03 °C) and Ubp3_Cat (47.09 ± 0.16 °C) share nearly identical melting temperatures, implying only the catalytic domain folds while the N-terminus is intrinsically disordered NanoDSF melting temperature data.

Complex architecture

SEC-SAXS of the co-expressed complex yielded a MoW2 molecular weight of 347.39 kDa versus 348.33 kDa predicted for a 2:2:2 Ubp3–Bre5–ubiquitin heterohexamer, consistent with Li et al.'s crystallographic finding of a hetero-tetrameric Ubp3–Bre5 core with a 119 nM binding interaction Ubp3-Bre5 crystal structure (2007). Because both proteins carry large IDRs, the authors used AlphaFold3, AFflecto, and BilboMD to fit flexible ensembles (χ² = 0.959 for Ubp3; χ² = 1.1 for Bre5), but the full complex fit poorly (χ² = 64.86), underscoring low-resolution uncertainty SAXS ensemble modelling details.

Critical caveats and blind spots

• In vitro vs in vivo gap: Cohen et al. proposed Bre5 confers substrate specificity (Sec23), not generic activity. The authors acknowledge this by reframing Bre5 as a substrate-recognition/localization cofactor rather than an activity switch — but no physiological substrates (Sec23, Atg19, eS7A) were tested in vitro, only Ub-AMC, Ub-GFP and Ub77N Authors.
• Data availability placeholders: SAXS deposition codes are literally 'XXX', limiting immediate reproducibility.
• Ub77N kinetic anomaly: The reported KM is ~100-fold higher than other USPs; the authors attribute this to obstructing loops and aggregation of full-length Ubp3 during freeze-thaw, which also means quantitative comparisons between Ubp3 and Ubp3_Cat may reflect differential stability, not regulation High KM anomaly discussion.
• Context from literature: Activity-based probes show Ubp3 is selectively enriched on Ub-PCNA probes, hinting at target-protein specificity the current constructs do not capture Ub-PCNA probe specificity for Ubp3. Ubp3 functions in ribophagy, DNA damage response, and ER-stress translation control also imply in vivo regulatory layers absent from this minimal system Ribophagy dependence on Ubp3.

Confidence: The in vitro activity claims are solidly supported by triplicate assays with appropriate inactive-mutant controls; the broader mechanistic re-interpretation of Bre5 is plausible but only weakly testable with the substrates used. Falsifying test: showing purified native Ubp3 substrates require Bre5 for cleavage would directly contradict the revised model.

 BGPT Paper Review

Study Novelty

First full-length in vitro SAXS/NanoDSF characterization of Ubp3, but the Ubp3-Bre5 hetero-tetramer was known since 2005-2007 and the activity reversal of a 2003 model is a correction rather than a new biological mechanism.

Scientific Quality

Appropriate controls (Ubp3C469A, Usp2, Bre5-only), triplicate assays, and multi-method validation; however placeholder SAXS accession codes ('XXX'), no atomic structure, and kinetic confounds from full-length Ubp3 degradation reduce quality.

Study Generality

Insights on IDR-containing DUB architecture and cofactor-independent catalysis apply broadly to USP enzymes, but findings are limited to one yeast protein pair in minimal artificial substrates.

Study Usefulness

Useful for DUB biochemists by correcting the Bre5 cofactor model and providing purification protocols; limited immediate translational value given USP10 homology questions remain untested.

Study Reproducibility

Detailed methods, buffers, and instruments are reported, but SAXS deposition codes are unfilled placeholders ('XXX') and quantitative kinetic parameters appear only in supplementary tables.

Explanatory Depth

Mechanistic level is solid (IDR/folded-domain architecture, 2:2:2 stoichiometry, catalytic-domain sufficiency) but substrate recognition and the physiologic role of Bre5 remain speculative.